Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to initiate clinical trials of its nintedanib esilate powder for inhalation, the first inhaled formulation cleared for clinical use in China for treating pulmonary fibrosis. Designed as an alternative to the existing oral soft capsule, the inhalation product aims to boost local lung exposure, improve lung function, reduce systemic exposure, and significantly cut gastrointestinal side effects, with preclinical data suggesting similar efficacy at 1/200 of the oral dose and a favorable safety profile; beyond idiopathic pulmonary fibrosis, the candidate may address systemic sclerosis-associated interstitial lung disease and progressive pulmonary fibrosis and is highlighted by the company as a milestone for its inhalation technology platform that could underpin a broader pipeline of inhaled therapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the research, development and commercialization of innovative drugs, with a growing focus on advanced delivery technologies such as inhalation formulations for respiratory and fibrotic diseases in the Chinese market.
Average Trading Volume: 123,980,945
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$96.97B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.